Item 8.01. Other Events. On February 18, 2025, Solid Biosciences Inc. (the “ Company”) issued a press release announcing the pricing of a $200.0 million underwritten offering, which is expected to close on February 19, 2025. Based upon the Company’s current operating plan, the Company estimates that the net proceeds from the offering, together with the Company’s existing cash, cash equivalents and available-for-salesecurities, will enable the Company to fund its operating expenses and capital expenditure requirements into the first half of 2027. The Company expects to use the net proceeds from the offering, together with its existing cash, cash equivalents and available-for-salesecurities, to fund research and development expenses, including advancing SGT-003and its other product candidates, and the remainder for general and administrative expenses and other general corporate purposes. The Company has based this estimate on assumptions that may prove to be wrong, and the Company could use its available capital resources sooner than it currently expects, in which case it would need to obtain additional funding, which may not be available to the Company on acceptable terms, or at all. The Company does not expect that its existing cash, cash equivalents and available-for-salesecurities and net proceeds from this offering alone will be sufficient to enable the Company to fund the completion of the development of any of its product candidates.